<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000691005"><TermName>Firmagon</TermName><TermPronunciation>(FER-muh-gon)</TermPronunciation><TermDefinition><DefinitionText>A drug that is used to treat advanced prostate cancer and is also being studied in the treatment 
of benign prostatic hyperplasia.  Firmagon binds to gonadotropin-releasing hormone (GnRH) 
receptors in the pituitary gland. This causes the body to stop making testosterone, which 
prostate cancer needs to grow. Firmagon is a type of GnRH antagonist. Also called degarelix.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000727616" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Firmagon&quot;" language="en" id="_3"/><MediaLink ref="CDR0000727615" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Firmagon&quot;" language="es" id="_4"/><SpanishTermName>Firmagon</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para tratar el cáncer de próstata en estadio avanzado; también está en estudio para tratar la hiperplasia prostática benigna. Firmagon se une a los receptores de la hormona liberadora de gonadotropina (GnRH) de la glándula pituitaria. Esto hace que el cuerpo deje de elaborar testosterona que el cáncer de próstata necesita para crecer. Firmagon es un tipo de antagonista de la GnRH. También se llama degarelix.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2010-12-09</DateFirstPublished><DateLastModified>2010-12-09</DateLastModified><RelatedInformation><RelatedDrugSummaryRef href="CDR0000631480">Degarelix</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
